论文部分内容阅读
构建携带人干扰素－γ（ＩＦＮ－γ）ｃＤＮＡ的逆转录病毒载体ｐＺＩＰ－ＩＦＮ－γ，上清感染法导入人肝癌细胞系ＨｅｐＧ２，分泌ＩＦＮ－γ活性为每４８ｈ０～２７３Ｕ／１０６。ＳｏｕｔｈｅｒｎＢｌｏｔ和ＳｌｏｔＢｌｏｔ验证目的基因的整合及表达。ＷｅｓｔｅｒｎＢｌｏｔ证明ＭＨＣＩ类分子的表达水平增加。体外混合淋巴细胞、肿瘤细胞培养，证实该瘤苗能刺激肝癌病人外周血淋巴细胞的增殖。该瘤苗还能增强ＨＬＡＡ２位点相匹配的肝癌病人外周血淋巴细胞的杀伤活性。结果表明，ＩＦＮ－γ基因修饰的肝癌细胞疫苗，能增强其免疫原性，具有潜在临床应用价值
The retroviral vector pZIP-IFN-γ carrying human interferon-γ (IFN-γ) cDNA was constructed and introduced into the human hepatocellular carcinoma cell line HepG2 by supernatant infection method. The activity of IFN-γ secretion was 0-273 U/106 per 48 h. SouthernBlot and SlotBlot verified the integration and expression of the target gene. WesternBlot demonstrated increased expression of MHC class I molecules. In vitro mixed lymphocyte and tumor cell culture confirmed that the tumor vaccine can stimulate the proliferation of lymphocytes in peripheral blood of patients with liver cancer. The tumor vaccine also enhances the killing activity of peripheral blood lymphocytes of liver cancer patients matched with HLAA2 locus. The results showed that the IFN-γ gene-modified hepatocellular carcinoma vaccine can enhance its immunogenicity and has potential clinical application value.